Skip to content
Open access

Targeted gene therapy alleviates epilepsy and hyperexcitability in models of SCN2A deficiency.

Nov 2026 · Journal of Clinical Investigation · 0 citations
Medicine

TL;DR

Proof of principle is provided for drug-controllable KCNA1 gene therapy as a promising treatment avenue for epilepsy related to SCN2A LoF variants by normalized elevated neuronal firing and reduced spontaneous seizure burden in Scn2a-deficient mice.

Abstract

Pathogenic SCN2A loss-of-function (LoF) variants can cause severe, refractory epilepsy with limited treatment options. Existing Scn2a-LoF mouse models exhibit few spontaneous seizures, limiting the dynamic range needed to assess therapeutic efficacy. We therefore generated gene-trap Scn2a-deficient mice on the seizure-prone DBA/2J background. These mice experienced hundreds of spontaneous absence seizures per day, characterized by concurrent behavioral arrest and EEG spike-wave discharges (SWDs). Partial restoration of Scn2a expression reduced seizure burden. Electrophysiological analysis revealed impaired action potential waveforms yet increased repetitive firing, alongside coordinated downregulation of voltage-gated potassium channel genes, potentially contributing to hyperexcitability. Given the broad potassium channel downregulation and prior efficacy of KCNA1 gene therapy in refractory seizure models, we selected KV1.1 as a potential therapeutic target and used a drug-controllable adeno-associated virus (AAV) to express human KCNA1. We found that this intervention normalized elevated neuronal firing and reduced spontaneous seizure burden in Scn2a-deficient mice. Extending these findings to a human cell-based platform, AAV-mediated KCNA1 expression also reduced neuronal firing in human cortical organoids carrying a SCN2A-truncating variant identified in patients. Together, these findings provide proof of principle for drug-controllable KCNA1 gene therapy as a promising treatment avenue for epilepsy related to SCN2A LoF variants.

Read PDF

Similar papers

Open access Sep 2026

Gene therapy with doxycycline-controlled expression of human Kv1.1 reduces neuronal excitability and increases sociability of Scn2a-deficient mice

Overall, the successful use of an inducible AAV-mediated gene delivery system to supplement hKv1.1 expression to mitigate neuronal hyperexcitability and ameliorate social impairments in a mouse model of SCN2A-related ASD is demonstrated.

Brody A. Deming, Jing-Liang Zhang, Iuliia Vitko et al. · 1 citation
Open access Oct 2026

Adeno-associated virus-mediated restoration of NaV1.1 in targeted brain regions ameliorates epilepsy in symptomatic Dravet syndrome mice.

OBJECTIVE Dravet syndrome (DS) is a developmental and epileptic encephalopathy primarily caused by haploinsufficiency of the SCN1A gene, which encodes the alpha subunit of NaV1.1 voltage-gated sodium channel. The disease manifests with febrile and spontaneous seizures, developmental delay, cognitive impairment, and inc...

Martina Mainardi, S. Brusco, S. Giannelli et al. · 0 citations
#gene editing Open access Oct 2026

Rapamycin rescues neuronal hyperexcitability and seizures driven by megalencephaly-causing AKT3 activation

The consistent therapeutic effects of mTOR inhibition across both systems support downstream targeting of the phosphoinositide 3-kinase–AKT–mTOR pathway as a rational therapeutic strategy for AKT3 -related epilepsy.

Yosuke Miyamoto, Takuma Mori, Mitsuru Ishikawa et al. · 0 citations
Open access Oct 2026

A Humanized Mouse Model of DRPLA Recapitulates Epilepsy and Demonstrates Antisense Oligonucleotide-Mediated Disease Modification

Dentatorubral-pallidoluysian atrophy (DRPLA) is an ultra-rare progressive myoclonus epilepsy caused by a glutamine-coding CAG repeat expansion in atrophin-1 (ATN1). Mutant ATN1 (mATN1) expression results in symptoms that inversely correlate to CAG-expansion size: young-onset cases have the most CAG repeats and developm...

Qian Wu, I. Erickson, Stephanie Davidson et al. · 0 citations
#gene editing Review Open access Nov 2026

Gene therapy for epilepsy: From SCN1A to broadened therapeutic horizons (Review).

Five nucleic acid‑based therapeutic strategies are examined, namely gene supplementation, enhancement of endogenous gene expression, gene silencing, DNA editing and RNA editing, for major causative genes, using mutation‑specific functional consequences [loss‑of‑function (LOF) vs. gain‑of‑function] as the primary framew...

Ruo-Tong Qin, Xiao-Ge Hu, Wei Jiang et al. · 0 citations
Open access Oct 2026

Closed-loop inhibitory metabotropic glutamate receptor gene therapy for focal refractory epilepsy.

Epilepsy is common and frequently refractory to anti-seizure medications. Although ablative surgery is effective when a seizure focus is identifiable, it is only suitable for a minority of patients because of risks of permanent neurological deficit. Several gene therapies for pharmacoresistant focal epilepsy are in dev...

Laura V. Ussingkær, D. Kullmann · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.